The role of SBRT as an ablative treatment in oligometastatic patients

Thumbnail Image

Files

The role of SBR.pdf (626.33 KB)
Identifiers
URI: https://hdl.handle.net/11268/17459
DOI: 10.1007/s12094-026-04462-x

Publication date

2026

Authors

Advisors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

SDG

goal-3

Metrics

Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Extracranial oligometastatic disease, defined as up to five metastases, represents an intermediate cancer state with potential for long-term control. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment associated with high local control, limited toxicity, and the ability to delay systemic therapy. This study reports institutional outcomes of SBRT across oligometastatic scenarios.

Description

UNESCO Subjects

Cáncer
Tratamiento médico
Investigación médica

Keywords

Bibliographic reference

Debén Méndez, B., Rodríguez Roldán, M., Garrido Botella, M. I., González Cantero, M., Teja Ubach, M., La Rosa, A., Rosel Aller, R., Belinchón Olmeda, B., Miralles Olivar, L., Enriquez, L. A. G., De Manso De Lema, A., Duque Santana, V., Díez Sebastián, J., & Gonzalez Del Portillo, E. (2026). The role of SBRT as an ablative treatment in oligometastatic patients. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04462-x
Editor's version
https://doi.org/10.1007/s12094-026-04462-x

Type of document

journal article

Collections

Área de Ciencias de la Salud